Menu
Trince (which stands for TRansfer INto CElls) is a Ghent University spin-off.
After several years of academic research, Trince was officially founded in December 2021.
Our main goal is to be active in all areas where physical transfection can contribute to more efficient cell engineering, from R&D to clinical applications. We offer an effective alternative transfection method to viral vectors and electroporation.
We see our technology being used within GMP and manufacturing settings, research, development, as well as tissue and stem cell engineering.
Most importantly, we position our gentle photoporation technology for use in GMP-compliant clinical settings for applications such as cell and gene therapy.
Philip is an experienced entrepreneur and CEO, having founded and/or headed several companies since 1998 including Versatel, a2z solutions, and Ovizio Imaging Systems. He has a background in engineering and an MBA from ESCP Business School.
Kevin is a professor and head of the bio-photonics research group at the University of Ghent. His main lines of research involve the development of biophotonics methods for drug delivery and biomedical diagnostics. In 2015, Kevin was awarded an ERC Consolidator Grant for his research on photoporation.
Wouter is an engineer and physicist with a specialty in photonics. Prior to working at Trince, he was a consultant to the automotive industry as an expert in software engineering. As the technical lead of Trince, he oversees the development of the LumiPoreTM platform.
Emilie Viey is a cellular biologist specializing in immunology. Her previous roles include working with Innate Pharma, Roche Diagnostics France, and ACEA Biosciences. From 2018-2022, Emilie was the CEO for Ovizio Imaging Systems, where she guided them to a global position in the bioprocessing market.
Molood has a background in cell biology, pharmaceuticals and nanomaterials. She received her PhD in pharmaceutical sciences from Ghent University in 2020.
Aranit completed his PhD in 2020 in the pharmaceutical sciences with a focus on cancer immunotherapy, nanotechnology, biophysics and cell engineering.
After gaining experience as a lab technician, Hayri was looking for a new challenge. In 2022 he joined the Trince team.
Stijn is a self-taught software developer. After the successful completion of his electronics degree, he started working for Trince to write and test our software.
After the successful completion of her studies in 2022, Hanna joined the Trince team permanently as office manager. She makes sure that daily operations are running smoothly!
Varun is an embedded software developer with a master’s in electronic Embedded Systems from ESIGELEC, France. He is involved with firmware development for the Lumipore platform
Stijn is a self-taught software developer. After the successful completion of his electronics degree, he started working for Trince to write and test our software.
After the successful completion of her studies in 2022, Hanna joined the Trince team permanently as office manager. She makes sure that daily operations are running smoothly!
Daisy Flamez is an experienced business developer with strong ties to Ghent University. Her business development work has included the IOF consortium BIOMARKED and the Cancer Research Institute of Ghent (CRIG).
She is also a partner in NXTGNT, the University of Ghent Center of Excellence in pharmacoepigenomics. In addition to her business background, she has a doctorate in biotechnology and molecular biology.
Cédric Van Nevel has a strong interest in new and upcoming technologies and the impact they can generate on our society and daily life. He started his career as a strategic consultant at Boston Consulting Group before building further experience in the energy sector through a number of management positions at Fluxys (ranging from M&A to construction). Prior to joining Qbic, Cédric was responsible for the venturing activities of Bekaert, actively scouting for relevant technologies, setting up collaborations and holding a number of advisory board positions in international funds. He holds an MSc in Electronics from the University of Ghent.
Jan is the founder of Novalis Biotech Incubation, and a serial entrepreneur in the food and biotech industry. Following his education in bio-engineering, he worked as senior consultant for the Boston Consulting Group and as an independent strategy consultant. Jan co-founded and served as director of Genohm, which was acquired by Agilent Technologies in 2018. Jan also served as director and chairman of Oystershell laboratories, a world-class developer of innovative consumer healthcare products. The company was acquired by Gilde Buy-Out Partners in 2017.
Jan is co-owner and director of Lipa Holding, a family business in food and recycling, and is operating partner in Victus Participations, an independent agri and food growth investment fund.
Jan obtained an MBA from INSEAD, and a Master in General Management from Vlerick Management School.
Patrick is an independent investor in several startups in medtech and other technologies. He is also chairman of Xeos Medical and Animab and board member at Clouds of Care. He was the Chief executive officer at the Nuscience group and is still chairman of Pegasus.
Philip is an experienced entrepreneur and CEO, having founded and/or headed several companies since 1998 including Versatel, a2z solutions, and Ovizio Imaging Systems. He has a background in engineering and an MBA from ESCP Business School.
Stefaan has been a professor at Ghent University since 1999 and is a world-renowned expert on advanced drug delivery. Currently he is the pro-dean of the Faculty of Pharmaceutical Sciences, and the director of the Ghent Research Group on Nanomedicines.
Novalis Biotech is an early-stage venture capital investor in the life sciences.
With an interest in innovative concepts in healthcare, Novalis aims to support their development at the earliest stages.
Novalis’ investment focus is “enabling technologies” in the life sciences, i.e. those that enable fast and comprehensive leaps in performance and capability. Focus areas include innovative research and manufacturing tools, bioinformatics, genomics, diagnostics and digital health.
Early-stage start-ups are given the most attention, from (pre-)seed stage to series A, and Novalis supports their evolution by providing funding, sharing professional and academic connections, and helping to shape a business strategy to create value for all stakeholders.
Novalis Biotech is an early-stage venture capital investor in the life sciences.
With an interest in innovative concepts in healthcare, Novalis aims to support their development at the earliest stages.
Novalis’ investment focus is “enabling technologies” in the life sciences, i.e. those that enable fast and comprehensive leaps in performance and capability. Focus areas include innovative research and manufacturing tools, bioinformatics, genomics, diagnostics and digital health.
Early-stage start-ups are given the most attention, from (pre-)seed stage to series A, and Novalis supports their evolution by providing funding, sharing professional and academic connections, and helping to shape a business strategy to create value for all stakeholders.
Working at Trince is like being welcomed into a family business. Everyone has their own part to play, and creativity and ideas are encouraged. If you’re looking for a position in a company that will treat you like an individual and not just another cog in the wheel, Trince is the place for you!
Do you think you have something to offer us? Check out our vacancies below or feel free to send your CV to hr@trincebio.com if you think your skills fit better somewhere else in our team.
Discover the latest news about Trince
Ottergemsesteenweg Zuid 731 | 9000 Gent | Belgium
Privacy Policy | Terms & Conditions | Cookie policy